Binding Site

Supplier Rating:

0 Reviews

Binding Site is a Specialist Protein company committed to the research, development, manufacture and distribution of innovative immunodiagnostic assays for the global laboratory market. With extensive expertise in antibody specificity technology, Binding Site gives clinicians and laboratory staff the tools to significantly improve diagnosis and management of patients across a range of cancers and immune system disorders.

Binding Site manufactures a wide range of high quality innovative products:

Freelite, a novel and highly significant tumour marker increasingly used for the diagnosis, prognosis and monitoring of Multiple Myeloma, a cancer of cells in the bone marrow. Multiple Myeloma is the second most common blood cancer after non-Hodgkin's lymphoma. There are currently approximately 2.5 million pairs of Freelite serum free light chain tests performed per annum with the number of laboratory analyses increasing at a rate of approx. 50% p.a.

Hevylite, a new tumour marker complementary to Freelite, was launched in 2009 and is expected to provide clinicians with further information to manage patients with Multiple Myeloma and similar disorders.

Primary Immunodeficiency Diseases (PID).

Binding Site is a market leader in the development of products for the investigation of PID (disorders in which part of the body’s immune system is missing or not functioning correctly). The current range of specialised products includes assays to measure specific antibody response to vaccination and assays to quantify immunoglobulins and IgG and IgA subclasses in human serum.

SPAPLUS is a fully supported, dedicated and reliable serum and plasma protein analyser which complements both the specialist Freelite, Hevylite and IgG subclass assays that Binding Site are well-known for, plus an expanding range of exciting new assays. The low maintenance SPAPLUS is compact, easy to use and provides a level of functionality usually seen only in larger systems.